1-6 of 6
Anne Marie O'Farrell
Close
Sort by
Journal Articles

A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease

Clinical Trials & Observations
Walter Fiedler, Hubert Serve, Hartmut Döhner, Michael Schwittay, Oliver G. Ottmann, Anne-Marie O'Farrell, Carlo L. Bello, Randy Allred, William C. Manning, Julie M. Cherrington, Sharianne G. Louie, Weiru Hong, Nicoletta M. Brega, Giorgio Massimini, Paul Scigalla, Wolfgang E. Berdel, Dieter K. Hossfeld
Journal: Blood
Blood (2005) 105 (3): 986–993.
https://doi.org/10.1182/blood-2004-05-1846
Published: 2005
Journal Articles

Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD–positive leukemic cells

Kevin W. H. Yee, Marcus Schittenhelm, Anne-Marie O'Farrell, Ajia R. Town, Laura McGreevey, Troy Bainbridge, Julie M. Cherrington, Michael C. Heinrich
Journal: Blood
Blood (2004) 104 (13): 4202–4209.
https://doi.org/10.1182/blood-2003-10-3381
Published: 2004
Journal Articles

SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes

Clinical Trials & Observations
Francis J. Giles, Alison T. Stopeck, Lewis R. Silverman, Jeffrey E. Lancet, Maureen A. Cooper, Alison L. Hannah, Julie M. Cherrington, Anne-Marie O'Farrell, Helene A. Yuen, Sharianne G. Louie, Weiru Hong, Jorge E. Cortes, Srdan Verstovsek, Maher Albitar, Susan M. O'Brien, Hagop M. Kantarjian, Judith E. Karp
Journal: Blood
Blood (2003) 102 (3): 795–801.
https://doi.org/10.1182/blood-2002-10-3023
Published: 2003
Journal Articles

SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo

Anne-Marie O'Farrell, Tinya J. Abrams, Helene A. Yuen, Theresa J. Ngai, Sharianne G. Louie, Kevin W. H. Yee, Lily M. Wong, Weiru Hong, Leslie B. Lee, Ajia Town, Beverly D. Smolich, William C. Manning, Lesley J. Murray, Michael C. Heinrich, Julie M. Cherrington
Journal: Blood
Blood (2003) 101 (9): 3597–3605.
https://doi.org/10.1182/blood-2002-07-2307
Published: 2003
Journal Articles

A model of APL with FLT3 mutation is responsive to retinoic acid and a receptor tyrosine kinase inhibitor, SU11657

Jastinder Sohal, Vernon T. Phan, Philip V. Chan, Elizabeth M. Davis, Bhumi Patel, Louise M. Kelly, Tinya J. Abrams, Anne Marie O'Farrell, D. Gary Gilliland, Michelle M. Le Beau, Scott C. Kogan
Journal: Blood
Blood (2003) 101 (8): 3188–3197.
https://doi.org/10.1182/blood-2002-06-1800
Published: 2003
Journal Articles

SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase

Kevin W. H. Yee, Anne Marie O'Farrell, Beverly D. Smolich, Julie M. Cherrington, Gerald McMahon, Cecily L. Wait, Laura S. McGreevey, Diana J. Griffith, Michael C. Heinrich
Journal: Blood
Blood (2002) 100 (8): 2941–2949.
https://doi.org/10.1182/blood-2002-02-0531
Published: 2002